Vancomycin Dosing for Second C. difficile Recurrence
For a second recurrence of C. difficile infection, use oral vancomycin in a tapered and pulsed regimen (125 mg four times daily for 10-14 days, then 125 mg twice daily for 7 days, then 125 mg once daily for 7 days, then 125 mg every 2-3 days for 2-8 weeks), regardless of renal function, as oral vancomycin is minimally absorbed systemically. 1
Key Treatment Principles
Standard Dosing Remains Unchanged
- The dose of oral vancomycin does NOT need adjustment for renal impairment because systemic absorption is negligible in patients with intact colonic mucosa 2, 3
- The standard 125 mg dose achieves fecal concentrations exceeding 2000 mg/L, which is three orders of magnitude higher than the MIC90 for C. difficile 3
- Higher doses (500 mg four times daily) do not improve outcomes for recurrent disease and only increase cost without clinical benefit 1, 4
Recommended Regimens for Second Recurrence
The IDSA/SHEA 2018 guidelines provide multiple equivalent options 1:
Tapered and pulsed vancomycin regimen (preferred):
- 125 mg four times daily × 10-14 days
- Then 125 mg twice daily × 7 days
- Then 125 mg once daily × 7 days
- Then 125 mg every 2-3 days × 2-8 weeks 1
Vancomycin followed by rifaximin:
- Vancomycin 125 mg four times daily × 10 days
- Followed by rifaximin 400 mg three times daily × 20 days 1
Fidaxomicin:
Fecal microbiota transplantation should be considered after failure of appropriate antibiotic regimens 1
Critical Renal Function Considerations
When Systemic Absorption May Occur
- Oral vancomycin can be absorbed systemically only in patients with severe colonic inflammation or mucosal disruption 6
- One pediatric case report documented serum vancomycin levels up to 17.8 mg/L in a patient with severe colitis and renal impairment, but levels normalized as colitis improved 6
- Monitor serum vancomycin levels only if the patient has:
Dose Adjustment NOT Required
- Even in patients with renal impairment, the standard 125 mg four times daily dose should be maintained because local intestinal concentrations—not systemic levels—determine efficacy 3
- The European guidelines confirm vancomycin 125 mg four times daily for second recurrence regardless of renal function 1
Important Clinical Pitfalls
Avoid These Common Errors
- Do not use metronidazole for second or subsequent recurrences due to inferior efficacy and cumulative neurotoxicity risk 1, 7, 8
- Do not increase vancomycin dose to 500 mg four times daily for recurrent disease—this is reserved only for fulminant CDI with ileus/shock 1, 9
- Do not discontinue therapy prematurely—the tapered/pulsed regimen requires weeks to months of treatment 1
- Avoid antiperistaltic agents and opiates entirely as they worsen outcomes and increase complications 1, 9
Monitoring in Elderly Patients
- Patients >65 years have increased nephrotoxicity risk even with oral vancomycin 2
- Monitor renal function during and after treatment in elderly patients, even those with normal baseline function 2
- Elderly patients may require longer treatment duration to achieve clinical response 2
Alternative Considerations
Fidaxomicin Advantage
- In patients with first recurrence, fidaxomicin reduced second recurrence rates to 19.7% versus 35.5% with vancomycin 5
- Early recurrence (within 14 days) occurred in only 8% with fidaxomicin versus 27% with vancomycin 5
- Consider fidaxomicin despite higher cost in patients with multiple risk factors for recurrence 1